|
1
|
Estey EH: Acute myeloid leukemia: 2013
update on risk-stratification and management. Am J Hematol.
88:318–327. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davis AS, Viera AJ and Mead MD: Leukemia:
An overview for primary care. Am Fam Physician. 89:731–738.
2014.PubMed/NCBI
|
|
3
|
Thein MS, Ershler WB, Jemal A, Yates JW
and Baer MR: Outcome of older patients with acute myeloid leukemia:
An analysis of SEER data over 3 decades. Cancer. 119:2720–2727.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stringaris K, Sekine T, Khoder A,
Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de
Lavallade H, Sarvaria A, et al: Leukemia-induced phenotypic and
functional defects in natural killer cells predict failure to
achieve remission in acute myeloid leukemia. Haematologica.
99:836–847. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maurillo L, Venditti A, Spagnoli A,
Gaidano G, Ferrero D, Oliva E, Lunghi M, D'Arco AM, Levis A,
Pastore D, et al: Azacitidine for the treatment of patients with
acute myeloid leukemia: Report of 82 patients enrolled in an
Italian Compassionate Program. Cancer. 118:1014–1022. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boultwood J and Wainscoat JS: Gene
silencing by DNA methylation in haematological malignancies. Br J
Haematol. 138:3–11. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tuominen R, Jewell R, van den Oord JJ,
Wolter P, Stierner U, Lindholm C, Johansson Hertzman C, Lindén D,
Johansson H, Frostvik Stolt M, et al: MGMT promoter methylation is
associated with temozolomide response and prolonged
progression-free survival in disseminated cutaneous melanoma. Int J
Cancer. 136:2844–2853. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iyama T and Wilson DM 3rd: DNA repair
mechanisms in dividing and non-dividing cells. DNA Repair (Amst).
12:620–636. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kraguljac Kurtović N, Krajnović M,
Bogdanović A, Suvajdžić N, Jovanović J, Dimitrijević B, Colović M
and Krtolica K: Concomitant aberrant methylation of p15 and MGMT
genes in acute myeloid leukemia: Association with a particular
immunophenotype of blast cells. Med Oncol. 29:3547–3556. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brandwein JM, Kassis J, Leber B, Hogge D,
Howson-Jan K, Minden MD, Galarneau A and Pouliot JF: Phase II study
of targeted therapy with temozolomide in acute myeloid leukaemia
and high-risk myelodysplastic syndrome patients pre-screened for
low O (6)-methylguanine DNA methyltransferase expression. Br J
Haematol. 167:664–670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fasan A, Alpermann T, Haferlach C,
Grossmann V, Roller A, Kohlmann A, Eder C, Kern W, Haferlach T and
Schnittger S: Frequency and prognostic impact of CEBPA proximal,
distal and core promoter methylation in normal karyotype AML: A
study on 623 cases. PLoS One. 8:e543652013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen C, Wang L, Liao Q, Huang Y, Ye H,
Chen F, Xu L, Ye M and Duan S: Hypermethylation of EDNRB promoter
contributes to the risk of colorectal cancer. Diagn Pathol.
8:1992013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vidal DO, Paixão VA, Brait M, Souto EX,
Caballero OL, Lopes LF and Vettore AL: Aberrant methylation in
pediatric myelodysplastic syndrome. Leuk Res. 31:175–181. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reid T, Oronsky B, Scicinski J, Scribner
CL, Knox SJ, Ning S, Peeh DM, Korn R, Stirn M, Carter CA, et al:
Safety and activity of RRx-001 in patients with advanced cancer: A
first-in-human, open-label, dose-escalation phase 1 study. Lancet
Oncol. 16:1133–1142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Malonia SK, Sinha S, Lakshminarasimhan P,
Singh K, Jalota-Badhwar A, Rampalli S, Kaul-Ghanekar R and
Chattopadhyay S: Gene regulation by SMAR1: Role in cellular
homeostasis and cancer. Biochim Biophys Acta. 1815:1–12.
2011.PubMed/NCBI
|
|
16
|
Johannes Z, Ina Radtke, Timothy S, Pardee,
Zhen Zhao, Amy R, Rappaport, Weijun Luo, Mila E, McCurrach, Yang
MM, Dolan ME, Kogan SC, et al: Mouse models of human AML accurately
predict chemotherapy response. Genes Dev. 23:877–889. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Poddighe PJ, Wessels H, Merle P, Westers
M, Bhola S, Loonen A, Zweegman S, Ossenkoppele GJ and Wondergem MJ:
Genomic amplification of MYC as double minutes in a patient with
APL-like leukemia. Mol Cytogenet. 7:672014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ofran Y and Rowe JM: Acute myeloid
leukemia in adolescents and young adults: Challenging aspects. Acta
Haematol. 132:292–297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pui CH: Acute leukemias with the
t(4;11)(q21;q23). Leuk Lymphoma. 7:173–179. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shahab F and Raziq F: Clinical
presentations of acute leukemia. J Coll Physicians Surg Pak.
24:472–476. 2014.PubMed/NCBI
|
